FOXR2 in cancer development: emerging player and therapeutic opportunities.

IF 4.1 4区医学 Q3 ONCOLOGY Oncology Research Pub Date : 2025-01-16 eCollection Date: 2025-01-01 DOI:10.32604/or.2024.052939

Piao Yang, Mohsen Sheykhhasan, Reza Heidari, Mohsen Chamanara, Paola Dama, Amirhossein Ahmadieh-Yazdi, Hamed Manoochehri, Hamid Tanzadehpanah, Hanie Mahaki, Naser Kalhor, Ashkan Dirbaziyan, Sharafaldin Al-Musawi

{"title":"FOXR2 in cancer development: emerging player and therapeutic opportunities.","authors":"Piao Yang, Mohsen Sheykhhasan, Reza Heidari, Mohsen Chamanara, Paola Dama, Amirhossein Ahmadieh-Yazdi, Hamed Manoochehri, Hamid Tanzadehpanah, Hanie Mahaki, Naser Kalhor, Ashkan Dirbaziyan, Sharafaldin Al-Musawi","doi":"10.32604/or.2024.052939","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer, a leading cause of global mortality, remains a significant challenge to increasing life expectancy worldwide. Forkhead Box R2 (FOXR2), identified as an oncogene within the FOX gene family, plays a crucial role in developing various endoderm-derived organs. Recent studies have elucidated FOXR2-related pathways and their involvement in both tumor and non-tumor diseases. Dysregulation of FOXR2 has been linked to numerous malignant tumors, spanning the brain, nervous system, thyroid, osteosarcoma, Hodgkin lymphoma, colorectal, liver, pancreatic, lung, breast, ovarian, prostate, female genital tract, endometrial, and uterine cancers. Despite extensive research on FOXR2 dysregulation, its practical applications remain underexplored. This review delves into the mechanisms underlying FOXR2 dysregulation during oncogenesis and its implications for cancer diagnosis, prognosis, and treatment.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 2","pages":"283-300"},"PeriodicalIF":4.1000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.052939","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer, a leading cause of global mortality, remains a significant challenge to increasing life expectancy worldwide. Forkhead Box R2 (FOXR2), identified as an oncogene within the FOX gene family, plays a crucial role in developing various endoderm-derived organs. Recent studies have elucidated FOXR2-related pathways and their involvement in both tumor and non-tumor diseases. Dysregulation of FOXR2 has been linked to numerous malignant tumors, spanning the brain, nervous system, thyroid, osteosarcoma, Hodgkin lymphoma, colorectal, liver, pancreatic, lung, breast, ovarian, prostate, female genital tract, endometrial, and uterine cancers. Despite extensive research on FOXR2 dysregulation, its practical applications remain underexplored. This review delves into the mechanisms underlying FOXR2 dysregulation during oncogenesis and its implications for cancer diagnosis, prognosis, and treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

FOXR2在癌症发展中的作用：新兴角色和治疗机会。

癌症是全球死亡的主要原因，仍然是全球预期寿命增加的重大挑战。叉头盒R2 （FOXR2）是FOX基因家族中的一个致癌基因，在多种内胚层来源器官的发育中起着至关重要的作用。最近的研究已经阐明了foxr2相关通路及其在肿瘤和非肿瘤疾病中的作用。FOXR2基因的失调与许多恶性肿瘤有关，包括脑癌、神经系统癌、甲状腺癌、骨肉瘤、霍奇金淋巴瘤、结直肠癌、肝癌、胰腺癌、肺癌、乳腺癌、卵巢癌、前列腺癌、女性生殖道癌、子宫内膜癌和子宫癌。尽管对FOXR2失调进行了广泛的研究，但其实际应用仍未得到充分探索。这篇综述深入探讨了FOXR2在肿瘤发生过程中的失调机制及其对癌症诊断、预后和治疗的意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.